Publications by Diane Augu-Denechere

Publications by authors named "Diane Augu-Denechere"

Page 1 of 1

A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.

Alicja Puszkiel Benoit You Léa Payen Jonathan Lopez Jérôme Guitton Diane Augu-Denechere

Cancer Chemother Pharmacol

May 2023

Article Synopsis

* Everolimus and sorafenib were given to patients on four dosing schedules, with tracking of biomarker responses and analysis using NONMEM software.
* A new dosing schedule (sorafenib 200 mg bid for 5 days on, 2 days off combined with continuous everolimus 5 mg qd) showed improved progression-free survival over the original trial regimen, leading to further evaluation.

View Article and Find Full Text PDF

Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.

Romain Varnier Alicja Puszkiel Michel Tod Sara Calattini Lea Payen Diane Augu-Denechere

Cancer Chemother Pharmacol

May 2023

Purpose: Everolimus (EVE) and sorafenib (SOR) combination was associated with synergistic activity in preclinical models. However, previous clinical studies were hampered by cumulative toxicities when both were given continuously. The academic EVESOR trial (NCT01932177) was designed to assess alternative doses and intermittent dosing schedules of EVE and SOR combination therapy to improve the benefit-risk ratio for patients with solid tumors.

View Article and Find Full Text PDF